ACE2 and COVID-19: Hence, a vicious cycle secondary to SARS-CoV-2 infection in patients with DM was proposed, in that the altered ACE2 binding of SARS-CoV-2 and compromised innate immunity of patients with DM increase their susceptibility to COVID-19 and COVID-19 induces pancreatic β-cell injury leading to a worse glycemic profile, which, in turn, impairs the immune response, induces a proinflammatory state and eventually aggravates COVID-19 progression and poor glycemic control.